Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first‐line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher‐risk populations with relapsed/refractory (R/R) disease. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Brien, Susan M., Byrd, John C., Hillmen, Peter, Coutre, Steven, Brown, Jennifer R., Barr, Paul M., Barrientos, Jacqueline C., Devereux, Stephen, Robak, Tadeusz, Reddy, Nishitha M., Kipps, Thomas J., Tedeschi, Alessandra, Cymbalista, Florence, Ghia, Paolo, Chang, Stephen, Ninomoto, Joi, James, Danelle F., Burger, Jan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593416/
https://www.ncbi.nlm.nih.gov/pubmed/30767298
http://dx.doi.org/10.1002/ajh.25436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593416/
https://www.ncbi.nlm.nih.gov/pubmed/30767298
http://dx.doi.org/10.1002/ajh.25436

Ejemplares similares